# Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure

> **NCT07708194** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 94 (estimated)

## Conditions studied

- Breast Cancer
- HER2-positive Breast Cancer
- Hormone Receptor-Positive Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** entinostat
- **DRUG:** Pyrotinib
- **DRUG:** endocrine therapy

## Key facts

- **NCT ID:** NCT07708194
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-23
- **Primary completion:** 2027-02
- **Final completion:** 2027-02
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2026-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07708194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07708194, "Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07708194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*